U.S. Commits $50M to Fast-Track PTSD Treatment Research

Millions of Americans living with PTSD may soon have access to breakthrough treatments that were once considered impossible to study.

President Trump signed an executive order on April 18 directing the FDA to accelerate research and approval of psychedelic-based therapies, including ibogaine and other compounds showing promise for treating post-traumatic stress disorder. The directive commits $50 million in federal research funding and creates faster pathways for drugs that receive Breakthrough Therapy designation.

The order represents a major shift in how the government approaches mental health treatment. For decades, substances like ibogaine remained locked in Schedule I classification, making clinical research nearly impossible despite growing evidence of therapeutic potential.

Under the new framework, federal agencies will work together to streamline approvals. The FDA, DEA, and VA will coordinate on expanded access for eligible patients through the Right to Try program, allowing those with serious conditions to access experimental treatments before full approval.

FDA Commissioner Marty Makary announced that decisions on some psychedelic drugs could come as soon as this summer. The order also instructs agencies to facilitate rescheduling of Schedule I substances after they complete successful Phase 3 trials, removing a major barrier that has slowed research for years.

The timing matters deeply for veterans and trauma survivors. While the FDA rejected MDMA-assisted therapy in 2024 over trial quality concerns, researchers have continued gathering data on multiple psychedelic compounds. The new funding and streamlined processes give these studies the resources and regulatory support they need to reach patients faster.

Companies developing these treatments have invested heavily in advocating for policy changes. Compass Pathways spent over $500,000 in recent lobbying efforts tied to psychedelic medicine regulation, while Mind Medicine focused on FDA and DEA guidance for clinical trials. Industry-wide lobbying has totaled several million dollars over the past decade, reflecting growing scientific consensus around therapeutic potential.

The Ripple Effect

This policy shift extends far beyond individual treatments. By creating clear pathways from research to approval, the order signals that the federal government recognizes mental health innovation as a national priority.

The $50 million investment will fund research across multiple institutions, training a new generation of clinicians in psychedelic-assisted therapy protocols. As these treatments move through trials, the expanded Right to Try access means eligible patients won't have to wait years for relief.

For veterans especially, the coordination between the VA and other agencies could transform care options. Traditional PTSD treatments help many people, but they don't work for everyone. Having additional evidence-based therapies available gives hope to those who haven't found relief through existing approaches.

The real impact will unfold over the coming months and years as research accelerates and patients gain access to new options that address the root causes of trauma rather than just managing symptoms.

Breakthrough treatments often start as ideas that seem impossible until suddenly they're not.